Global Assisted Reproductive Technology Market

Global Assisted Reproductive Technology Market was valued at USD 41.02 Bn in 2025 and is expected to reach USD 78.93 Bn by 2032, growing at a CAGR of 9.8% during the forecast period.

Assisted Reproductive Technology Market Overview:

In vitro fertilization is a method in which eggs are surgically removed from the female ovaries and fused with laboratory sperms. They are either transferred to different females or returned to the ovaries after the process is completed. ART can be used to eliminate infertility problems while keeping the genetic link intact.To know about the Research Methodology :- Request Free Sample Report

Assisted Reproductive Technology Market Dynamics:

Rising prevalence of infertility issues is the major factor driving the market growth.

According to the Centres for Disease Control and Prevention (CDC), 12.1% of women between the ages of 15 and 44 in the United States have impaired fecundity, while 6.7% of women from the same age group are infertile. As a result, demand for ART technology is projected to rise. As a result, the rise in infertility cases around the world is likely to drive market growth in the forecast years. Over the forecast period, other factors such as an increase in the number of single women and same-sex couples, as well as increased knowledge of IVF and surrogacy, are likely to fuel market growth. One of the major elements of market growth is technological advancements. VitriCell SA reported the conclusion of a USD 1.2 million loans in January 2018. These funds are expected to help the company launch aseptic vitrification-based goods (new cell cryopreservation technique). In the forecast years, this is projected to have a favourable impact on the ART market. Other factors driving market growth include rising tobacco and alcohol consumption, increasing marital age, and rising obesity rates.

Because of reasons such as newer contraceptive procedures and a growing number of women favouring professions over raising a family, the median age of first-time parenthood is rising. Furthermore, in industrialized countries, the rate of first-time pregnancies among women under the age of 20 has declined quickly, which is one of the primary causes fuelling the Assisted Reproductive Technology market growth. However, one of the primary reasons expected to slow the growth of the Assisted Reproductive Technology Market is the high cost of assisted reproductive technologies to treat infertility.

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Assisted Reproductive Technology Market Segment Analysis:

• In 2025, the Technology segment is dominated by In Vitro-Fertilization (IVF), as it remains the most widely used and effective assisted reproductive procedure for treating various infertility conditions. IVF is preferred by fertility specialists due to its higher success rates and the ability to combine it with advanced techniques such as genetic screening and embryo freezing. Artificial Insemination (AI-IUI) also holds a significant share as a less invasive and cost-effective fertility treatment, especially for couples with mild infertility issues. Frozen Embryo Replacement (FER) is experiencing strong growth due to improvements in embryo cryopreservation technologies, allowing embryos to be stored and transferred in later cycles with improved success rates. Other ART technologies, including intracytoplasmic sperm injection and donor-based reproductive procedures, are also contributing to the expansion of this segment.

• Based on End User, Fertility Clinics represent the largest and most demanded segment in 2025. These clinics specialize in reproductive medicine and are equipped with advanced laboratories, embryo culture systems, and experienced fertility specialists, enabling them to provide comprehensive ART treatments such as IVF, embryo freezing, and genetic testing. Hospitals also contribute significantly to the market by offering fertility treatments within obstetrics and gynecology departments, particularly in large healthcare institutions and academic medical centers. The Others segment includes research institutes and specialized reproductive centers that provide diagnostic, laboratory, and supportive fertility services.

• In terms of Patient Type, Female Infertility accounts for the largest share of the Assisted Reproductive Technology market in 2025. Conditions such as ovulation disorders, endometriosis, and blocked fallopian tubes are key factors driving demand for ART procedures among women. Male Infertility is also an important segment, with increasing cases of low sperm count, reduced sperm motility, and genetic disorders encouraging the use of advanced techniques like intracytoplasmic sperm injection (ICSI). Combined Infertility, where both partners experience fertility issues, is also contributing to the growth of the market, as couples increasingly rely on ART procedures to improve their chances of successful pregnancy.

• Based on Age Group, the 30–40 Years segment holds the highest demand in 2025, as many individuals and couples delay parenthood due to career priorities, lifestyle factors, and financial planning. This age group often seeks ART treatments when natural conception becomes more difficult. The Below 30 Years segment also contributes to the market, particularly among patients with medical infertility conditions that require early intervention. The Above 40 Years segment is growing steadily as well, driven by advancements in reproductive technologies, donor egg programs, and improved fertility treatment success rates for older patients.

 Regional Insights:

Based on Region, North America leads the Global Assisted Reproductive Technology Market in 2025 due to advanced healthcare infrastructure, strong awareness of fertility treatments, and the presence of leading fertility clinics and biotechnology companies. The region benefits from significant investments in reproductive medicine and widespread adoption of advanced ART procedures. Europe also holds a substantial market share supported by favorable healthcare policies and increasing fertility treatment programs in countries such as the UK, Germany, and Spain. Asia Pacific is expected to experience the fastest growth during the forecast period due to rising infertility rates, expanding healthcare infrastructure, and increasing medical tourism in countries such as India, China, and Japan. Meanwhile, Middle East & Africa and South America are witnessing gradual growth as awareness of fertility treatments improves and access to reproductive healthcare services expands.

Assisted Reproductive Technology Market Scope: Inquire before buying

Assisted Reproductive Technology Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (razil, Argentina Rest of South America)

Key Players /Competitor Profiles Covered in the Global Assisted Reproductive Technology Market Report from a Strategic Perspective

1. California Cryobank
2. Bloom IVF Centre
3. Parallabs
4. OvaScience
5. Anecova
6. Origio
7. Microm Ltd.
8. Merck KGaA
9. CooperSurgical Inc.
10. Ferring Pharmaceuticals
11. Cosmos Biomedical Limited
12. Cryolab Ltd.
13. European Sperm Bank
14. FUJIFILM Irvine Scientific
15. Vitrolife AB
16. Hamilton Thorne Ltd.
17. Cook Medical
18. Thermo Fisher Scientific Inc.
19. Genea Pty Ltd.
20. Genea Biomedx
21. Monash IVF Group
22. Virtus Health
23. INVO Bioscience
24. IVI RMA Global
25. Progyny Inc.